INOVIO Pharmaceuticals Leadership

J. Joseph Kim is the president and chief executive officer of [Inovio Pharmaceuticals](https://www.crunchbase.com/organization/inovio-pharmaceuticals), a pharmaceutical company that develops cancer and chronic infectious disease vaccines for preventive and therapeutic purposes. In 2000, he co-founded VGX Pharmaceuticals to develop intellectual property related to immunotherapeutic licensed from the University of Pennsylvania. Previously, Kim served as a senior vaccine developer at Merck & Co., where he led efforts in manufacturing and process development for several FDA-approved products for hepatitis and developmental vaccines and therapeutics for HIV. In 2015, he was selected as the entrepreneur of the year for Greater Philadelphia by Ernst & Young. He has published over 100 scientific papers, holds numerous patents, and sits on several editorial boards and review panels. Kim holds a Bachelor of Science degree in chemical engineering and economics from the Massachusetts Institute of Technology, where he was a U.S. Senate Honors Scholar. He obtained his PhD in biochemical engineering from the University of Pennsylvania and Master of Business Administration degree in finance from the Wharton School.

Accomplished life sciences senior executive known as a catalyst for growth and transformation through innovation and collaboration. Proven track record of success within start-up, biotechnology, and publicly traded biopharmaceutical companies in the US and Europe, with operations globally. Demonstrated commercial acumen combined with strong scientific base in molecular biology, immunology and infectious disease. Build and lead high performing, cross organizational teams to successfully deliver complex development projects. Multiple leadership roles in transactions, including company formation, mergers, acquisitions, licensing and asset sales. Significant experience working with the public sector, including academic partners, technology transfer offices, not for profit institutions, Foundations, and NGOs. Exemplary communication and motivation skills, skilled at interacting at all levels within an organization. Areas of strength include:Strategic Planning | Operational Management | Product Development |Alliance/Project Management | Financial Management | Corporate Development | Fundraising | Corporate Communications | Donor/Investor Relations | Change Management

Laurent Humeau is the Chief Scientific Officer and Executive Vice President of Research, Engineering and Clinical Developments for Inovio. Prior to that, he was the Senior Director for Translational Research, Human Therapeutics Division at Intrexon Corporation.

Peter Kies works at INOVIO PHARMACEUTICALS, INC. and a CFO at INOVIO PHARMACEUTICALS, INC. and is based in Escondido, California.

J. Joseph Kim is the president and chief executive officer of [Inovio Pharmaceuticals](https://www.crunchbase.com/organization/inovio-pharmaceuticals), a pharmaceutical company that develops cancer and chronic infectious disease vaccines for preventive and therapeutic purposes. In 2000, he co-founded VGX Pharmaceuticals to develop intellectual property related to immunotherapeutic licensed from the University of Pennsylvania. Previously, Kim served as a senior vaccine developer at Merck & Co., where he led efforts in manufacturing and process development for several FDA-approved products for hepatitis and developmental vaccines and therapeutics for HIV. In 2015, he was selected as the entrepreneur of the year for Greater Philadelphia by Ernst & Young. He has published over 100 scientific papers, holds numerous patents, and sits on several editorial boards and review panels. Kim holds a Bachelor of Science degree in chemical engineering and economics from the Massachusetts Institute of Technology, where he was a U.S. Senate Honors Scholar. He obtained his PhD in biochemical engineering from the University of Pennsylvania and Master of Business Administration degree in finance from the Wharton School.

J. Joseph Kim is the president and chief executive officer of [Inovio Pharmaceuticals](https://www.crunchbase.com/organization/inovio-pharmaceuticals), a pharmaceutical company that develops cancer and chronic infectious disease vaccines for preventive and therapeutic purposes. In 2000, he co-founded VGX Pharmaceuticals to develop intellectual property related to immunotherapeutic licensed from the University of Pennsylvania. Previously, Kim served as a senior vaccine developer at Merck & Co., where he led efforts in manufacturing and process development for several FDA-approved products for hepatitis and developmental vaccines and therapeutics for HIV. In 2015, he was selected as the entrepreneur of the year for Greater Philadelphia by Ernst & Young. He has published over 100 scientific papers, holds numerous patents, and sits on several editorial boards and review panels. Kim holds a Bachelor of Science degree in chemical engineering and economics from the Massachusetts Institute of Technology, where he was a U.S. Senate Honors Scholar. He obtained his PhD in biochemical engineering from the University of Pennsylvania and Master of Business Administration degree in finance from the Wharton School.

Accomplished life sciences senior executive known as a catalyst for growth and transformation through innovation and collaboration. Proven track record of success within start-up, biotechnology, and publicly traded biopharmaceutical companies in the US and Europe, with operations globally. Demonstrated commercial acumen combined with strong scientific base in molecular biology, immunology and infectious disease. Build and lead high performing, cross organizational teams to successfully deliver complex development projects. Multiple leadership roles in transactions, including company formation, mergers, acquisitions, licensing and asset sales. Significant experience working with the public sector, including academic partners, technology transfer offices, not for profit institutions, Foundations, and NGOs. Exemplary communication and motivation skills, skilled at interacting at all levels within an organization. Areas of strength include:Strategic Planning | Operational Management | Product Development |Alliance/Project Management | Financial Management | Corporate Development | Fundraising | Corporate Communications | Donor/Investor Relations | Change Management

Laurent Humeau is the Chief Scientific Officer and Executive Vice President of Research, Engineering and Clinical Developments for Inovio. Prior to that, he was the Senior Director for Translational Research, Human Therapeutics Division at Intrexon Corporation.